A study supports targeted conversion of kidney transplant recipients with a history of cutaneous squamous cell carcinoma ...

A recently published study suggests that sirolimus is an attractive treatment option for the prevention of secondary skin cancer in kidney transplant recipients. However, before we think about ...

The two medications can be administered concomitantly if various factors are taken into account. CHICAGO—Clinicians can safely use sirolimus and voriconazole concurrently if certain steps are followed ...

Please provide your email address to receive an email when new articles are posted on . One glass of grapefruit juice each day significantly slowed the body’s metabolism of sirolimus, suggesting ...

Acute GVHD (aGVHD) is a major cause of morbidity and mortality in hematopoietic allograft recipients. The best therapy for patients failing to respond, or not tolerating, systemic glucocorticoids ...

Background: Sirolimus-eluting stents have recently been shown to reduce the risk of restenosis among patients who undergo percutaneous coronary intervention (PCI). Given that sirolimus-eluting stents ...

Sirolimus, when used instead of calcineurin inhibitors in transplant patients, could reduce the incidence and delay the occurrence of a repeat squamous-cell cancer of the skin, according to a recent ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

CINCINNATI - The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a tumor called angiomyolipomata in patients ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...

Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial Sarcomas are a ...

Newark, May 22, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 250 million in 2023 global sirolimus market will reach USD 370.06 million in 2033. Sirolimus is also known as ...